Breaking News

Financial Report: Anacor Pharmaceuticals

May 10, 2013

Decline in R&D agreements impacts revenues

Anacor Pharmaceuticals

1Q Revenues: $1.7 million (-29%)

1Q Loss: $15.1 million (loss of $14.3 million in 1Q12)

Comments: Contract revenue decline was due to a decrease in research work performed under R&D agreements. R&D expenses were $11.2 million, down 12%. On April 5, 2013, the company entered a research agreement with the Gates Foundation to discover drug candidates to treat elephantiasis and tuberculosis. Anacor will receive as much as $17.7 million over three years for research activities.
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus